Table 1 Sociodemographic and clinical characteristics of study sample
Characteristic | SMM Participants(N = 15) | MM Participants(N = 6) |
|---|---|---|
Age (years) | ||
Mean (SD) | 61.4 (9.2) | 53.0 (8.9) |
Median (Range) | 61.0 [46.0–78.0] | 54.0 [39.0–62.0] |
Gender, n (%) | ||
Male | 4 (26.7%) | 1 (16.7%) |
Female | 11 (73.3%) | 5 (83.3%) |
Ethnicity, n (%) | ||
Hispanic or Latino | 1 (6.7%) | 1 (16.7%) |
Not Hispanic or Latino | 14 (93.3%) | 5 (83.3%) |
Racial Background, n (%) | ||
White | 5 (33.3%) | 4 (66.7%) |
Black or African American | 7 (46.7%) | 1 (16.7%) |
Asian | 1 (6.7%) | 0 (0.0%) |
Othera | 2 (13.3%) | 1 (16.7%) |
Living/Domestic Situation, n (%) | ||
Living alone | 1 (6.7%) | 0 (0.0%) |
Living with a partner or spouse, family, or friends | 14 (93.3%) | 6 (100.0%) |
Employment status, n (%) | ||
Employed, full-time | 9 (60.0%) | 1 (16.7%) |
Employed, part-time | 0 (0.0%) | 1 (16.7%) |
Unemployed | 0 (0.0%) | 2 (33.3%) |
Retired | 4 (26.7%) | 0 (0.0%) |
Disabled | 1 (6.7%) | 2 (33.3%) |
Otherb | 1 (6.7%) | 0 (0.0%) |
Highest Level of Education, n (%) | ||
Less than high school | 1 (6.7%) | 0 (0.0%) |
Completed high school | 2 (13.3%) | 1 (16.7%) |
Associate degree, technical or trade school | 2 (13.3%) | 1 (16.7%) |
Some college | 2 (13.3%) | 1 (16.7%) |
College | 5 (33.3%) | 2 (33.3%) |
Graduate school | 3 (20.0%) | 1 (16.7%) |
Marital Status, n (%) | ||
Married | 15 (100.0%) | 4 (66.7%) |
Single | 0 (0.0%) | 1 (16.7%) |
Divorced | 0 (0.0%) | 1 (16.7%) |
Time since SMM/MM diagnosis (years) | ||
Mean (SD) | 2.6 (2.0) | 1.9 (2.1) |
Median (Range) | 2.3 [0.1–6.9] | 0.7 [0.2–4.8] |
Other health conditions d, n (%) | ||
Allergic rhinitis | 1 (6.7%) | 0 (0.0%) |
Anxiety | 1 (6.7%) | 1 (16.7%) |
Arthritis | 2 (13.3%) | 0 (0.0%) |
Cardiovascular disease | 1 (6.7%) | 0 (0.0%) |
Hypertension (high blood pressure) | 4 (26.7%) | 1 (16.7%) |
Kidney Disease | 0 (0.0%) | 1 (16.7%) |
Pulmonary Disease | 0 (0.0%) | 1 (16.7%) |
Osteoporosis | 0 (0.0%) | 1 (16.7%) |
Otherc | 3 (20.0%) | 2 (33.3%) |
No other health conditions | 7 (46.7%) | 4 (66.7%) |
Current Treatments for SMM/ MMd, n (%) | ||
Iron Supplement | 1 (6.7%) | 0 (0.0%) |
Carfilzomib, Dexamethasone, Lenalidomide | 0 (0.0%) | 1 (16.7%) |
Bortezomib, Cyclophosphamide, Decadron | 0 (0.0%) | 1 (16.7%) |
Bortezomib, Lenalidomide, Dexamethasone, Prednisone | 0 (0.0%) | 1 (16.7%) |
Velcade, Dexamethasone | 0 (0.0%) | 1 (16.7%) |
No Treatment | 14 (93.3%) | 2 (33.3%) |